Cellectis SA(CLLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLLS Cellectis SA

Closed 12-11 16:00:00 EST

5.22

+0.09

+1.75%

盘后5.22

+0.000.00%

16:04 EST

High5.45	Low5.15	Vol219.27K
Open5.15	D1 Closing5.13	Amplitude5.85%
Mkt Cap522.00M	Tradable Cap349.27M	Total Shares100.00M
T/O1.16M	T/O Rate0.33%	Tradable Shares66.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLLS","market":"US","secType":"STK","nameCN":"Cellectis SA","latestPrice":5.22,"timestamp":1765486800000,"preClose":5.13,"halted":0,"volume":219268,"hourTrading":{"tag":"盘后","latestPrice":5.22,"preClose":5.22,"latestTime":"16:04 EST","volume":439,"amount":2291.58,"timestamp":1765487057390},"delay":0,"floatShares":66909900,"shares":100000000,"eps":-0.353485,"marketStatus":"Closed","change":0.09,"latestTime":"12-11 16:00:00 EST","open":5.15,"high":5.45,"low":5.15,"amount":1158512.3754,"amplitude":0.05848,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.353485,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765530000000},"marketStatusCode":5,"adr":1,"adrRate":1,"listingDate":1427256000000,"exchange":"NASDAQ","adjPreClose":5.13,"preHourTrading":{"tag":"盘前","latestPrice":5.15,"preClose":5.13,"latestTime":"09:29 EST","volume":5569,"amount":28501.653598700002,"timestamp":1765463370009},"postHourTrading":{"tag":"盘后","latestPrice":5.22,"preClose":5.22,"latestTime":"16:04 EST","volume":439,"amount":2291.58,"timestamp":1765487057390},"volumeRatio":2.139346,"impliedVol":2.8151,"impliedVolPercentile":0.956},"requestUrl":"/m/hq/s/CLLS/tweets","defaultTab":"tweets","newsList":[{"id":"2590510653","title":"European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2590510653","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590510653?lang=en_us&edition=fundamental","pubTime":"2025-12-12 00:10","pubTimestamp":1765469447,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were on the rise late Thursday morning, increasing 0.82% to 1,663.66 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion  and biopharmaceutical firm Cellectis , which rose 4.6% and 3.9%, respectively. They were followed by telecommunications company Nokia  and pharmaceutical firm Novo Nordisk , which advanced 3.6% and 2.6% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications  and medical device maker EDAP TMS , which fell 3.8% and 1.7% respectively. They were followed by oil and gas company Eni  and petroleum refiner Equinor , which were off 0.2% each.From the UK and Ireland, the gainers were led by cruise line operator Carnival  and biopharmaceutical company Akari Therapeutics , which increased 4% and 3.4% respectively. They were followed by communications company WPP  and alcoholic beverage company Diageo , whic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BDRX","E","EDAP","EVAX","SNN","BK4107","BK4007","BK4532","IE00BZ1G4Q59.USD","BK4082","WPP.AU","CLLS","DGE.UK","IE00BMPRXR70.SGD","BK4547","LU0154236417.USD","WPP","IE00BMPRXN33.USD","BK4169","NCNA","BK4585","BK7104","BK4588","BK4201","AKTX","NOK","BK4139","BK4141","DEO","BK4117","LU1093756325.SGD","EQNR","BK4599","SQNS","BCYC","AFG","IE00BKVL7J92.USD","BK4142","CUK","LU1093756168.USD","BK4020","BK4009","NVO.AU","BK4559"],"gpt_icon":1},{"id":"2590539837","title":"European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2590539837","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590539837?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:08","pubTimestamp":1765382894,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were heading higher late Wednesday morning, rising 0.67% to 1,636.27 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies  and Cellectis , which climbed 14% and 6.8%, respectively. They were followed by pharmaceutical company Novo Nordisk  and brewing company Anheuser-Busch InBev , which advanced 3.8% and 1.8%, respectively.The decliners from continental Europe were led by biotech firm Evaxion  and semiconductor company Sequans Communications , which fell 3.8% and 2.1%, respectively. They were followed by internet advertising firm Criteo  and medical device maker EDAP TMS , which were down 1.9% each.From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals  and lender HSBC , which rose 33% and 4.1%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics  and educational publish","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","BK4082","NVO","BCYC","BK4141","BK4158","LU0310800965.SGD","LU1093756325.SGD","BUD","NCNA","SQNS","BK4521","BK4107","BK4588","HSBC","00005","BK4111","BK4207","AKTX","BK4139","BK4204","BK4599","LU0128525689.USD","EVAX","LU1093756168.USD","TRIB","LU0052756011.USD","CRTO","BK4009","PSO","BDRX","BK7119","BK4007","BK4117","DBVT","IE00BZ1G4Q59.USD","AMRN","BK4585","LU1267930227.SGD","CLLS","BK4532","IE00BKVL7J92.USD","IE00BFMHRM44.USD","LU2236285917.USD","LU0154236417.USD","EDAP"],"gpt_icon":1},{"id":"2589828533","title":"ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589828533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589828533?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:30","pubTimestamp":1765175400,"startTime":"0","endTime":"0","summary":"Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201199/0/en/ASH-2025-Cellectis-Presents-Development-Plan-to-Further-Enhance-High-Response-Rate-Observed-for-Eti-cel-in-r-r-NHL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","CLLS","ASH","BK4161","CR","BK4139","LU2463526074.USD","ORR"],"gpt_icon":0},{"id":"2586266977","title":"European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2586266977","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586266977?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:03","pubTimestamp":1764172980,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were surging higher late Wednesday morning, rising 1.25% to 1,614.11 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical companies Novo Nordisk  and Ascendis Pharma , which rose 3.5% and 1.8%, respectively. They were followed by biopharmaceutical company DBV Technologies  and lender Banco Santander , which were up 1.7% and 1.6%, respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis  and brewing company Anheuser-Busch InBev , which fell 4.6% and 1%, respectively. They were followed by biotech firm Evaxion  and pharmaceutical company Sanofi , which were off 0.9% each.From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics  and NuCana , which increased 5.5% and 3.7%, respectively. They were followed by lenders Barclays  and Lloyds Banking Group , which advanced 3.2% each.The decliners from the","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4107","SNY","LU0109394709.USD","BK4505","BK4007","LYG","ASND","LU0889565916.HKD","IE00BFXG1179.USD","MREO","AUTL","BK4207","SAN.AU","BK4158","BK7119","EVAX","BK4139","BK4117","NVO.AU","SAN","BK4521","DEO","BK4559","CLLS","BCS","DBVT","LU1093756168.USD","NCNA","BUD","BK4532","DGE.UK","IE00BZ1G4Q59.USD","BUD.AU","BK4599","BK4169","LU0320765992.SGD","IE00BKVL7J92.USD","BCYC","BK7104","AKTX","BK4588","AFG","BK4585","NVO","LU1093756325.SGD","BK7142","LU0154236417.USD"],"gpt_icon":1},{"id":"2586562496","title":"European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2586562496","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586562496?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:14","pubTimestamp":1764000859,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts opened the week little changed late Monday morning, edging 0.1% higher to 1,572.55 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and internet browser company Opera , which advanced 10% and 2.4%, respectively. They were followed by medical device maker EDAP TMS  and telecommunications company Nokia , which increased 1.7% and 1.5%, respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk  and internet advertising firm Criteo , which fell 7.8% and 1.4%, respectively. They were followed by oil and gas company Eni , which was down 1%.From the UK and Ireland, the gainers were led by biopharmaceutical companies Mereo BioPharma Group  and Bicycle Therapeutics , which rose 3.6% each. They were followed by biotech firm Trinity Biotech  and biopharmaceutical company NuCana , which were up 3.2% and 1.7%, respectively","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NVO.AU","BK4117","LU0154236417.USD","IE00BKVL7J92.USD","BK4505","MREO","CLLS","WPP","BK4201","NOK","BK4020","BK4588","TRIB","BK4009","LU1093756168.USD","NVO","IE00BFMHRM44.USD","NGG","BK7104","BK4023","BK4599","BDRX","EDAP","LU1093756325.SGD","BK4139","BCYC","BK4107","BK4208","BK4082","BK4547","EVAX","OPRA","WPP.AU","BK4532","CRTO","AFG","E","IE00BZ1G4Q59.USD","NCNA","IE00BMPRXR70.SGD","AKTX","IE00BMPRXN33.USD","BK4585"],"gpt_icon":1},{"id":"2585890142","title":"European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2585890142","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585890142?lang=en_us&edition=fundamental","pubTime":"2025-11-22 00:01","pubTimestamp":1763740869,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were tracking higher Friday morning, rising 0.65% to 1,561.36 on the S&P Europe Select ADR Index, which is down close to 3% for  the wee","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTLS","BK4142","UN","BK4075","BK4023","SLN","IHG","EVAX","NCNA","BK4559","BK4204","BK4183","BUD","BK7119","BK7062","LU0124676726.USD","LU0689626769.HKD","BK4115","BUD.AU","BK4169","OPRA","PSO","AFG","BK4139","BK4158","BK4111","DEO","BCYC","BTI","BTI.AU","DGE.UK","ULVR.UK","BK4592","UL","BK4107","SQNS","AUTL","BK4117","BK4141","BK4546","CLLS","LU0006061336.USD","BK4585","BK4588","LU2543165471.USD","TEF"],"gpt_icon":0},{"id":"2584785259","title":"Why Cellectis Stock Is Trading Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2584785259","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584785259?lang=en_us&edition=fundamental","pubTime":"2025-11-20 03:12","pubTimestamp":1763579520,"startTime":"0","endTime":"0","summary":"Cellectis reports strong Nature Communications data showing CssDNA boosts non-viral gene insertion efficiency and supports long-term therapeutic potential.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/19/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/19/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/biotech/25/11/48959138/why-cellectis-stock-is-trading-higher-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/25/11/48959138/why-cellectis-stock-is-trading-higher-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["CLLS","BK4139"],"gpt_icon":0},{"id":"2584394825","title":"Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2584394825","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584394825?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:18","pubTimestamp":1763551080,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  19, 2025  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190757/0/en/Cellectis-Publishes-Nature-Communications-Article-on-a-Non-Viral-Gene-Editing-Process-Enabling-Efficient-Gene-Insertion-in-Hematopoietic-Stem-Cells.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","BK4139"],"gpt_icon":0},{"id":"2584627021","title":"European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2584627021","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584627021?lang=en_us&edition=fundamental","pubTime":"2025-11-18 00:19","pubTimestamp":1763396365,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were slightly lower late Monday morning, edging 0.1% lower to 1,610.86 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and pharmaceutical company Ascendis Pharma , which climbed 7.5% and 7.2%, respectively. They were followed by biopharmaceutical companies DBV Technologies  and Genfit , which advanced 5.4% and 3.5%, respectively.The decliners from continental Europe were led by software firm SAP  and lender Banco Santander , which fell 1.9% each. They were followed by brewing company Anheuser-Busch InBev  and health technology company Philips , which were down 1.6% and 1.4%, respectively.From the UK and Ireland, the gainers were led by communications company WPP  and biopharmaceutical company Mereo BioPharma Group , which rose 11% and 2.5%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics  and pharmaceutical compan","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","GNFT","BK4158","BK4521","WPP","BK4117","NCNA","BK4528","BK4139","CLLS","GSK","SAP","BUD.AU","BDRX","BK4585","BK4505","LU0320765992.SGD","BK4532","ASND","BK4007","BK4107","MREO","GNFTY","PHG","TRIB","DBVT","SAN.AU","BK4207","BK4082","BK4613","BCYC","GSK.UK","LU0109394709.USD","BK4588","BK7142","WPP.AU","BK4009","AKTX","LU1829250122.USD","BUD","LU0889565916.HKD","AFG","SAN","BK7119"],"gpt_icon":0},{"id":"2582039086","title":"Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2582039086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582039086?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:16","pubTimestamp":1762895809,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their neutral stance on CLLS stock, giving a Hold rating today. Soumit Roy has given his Hold rating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-for-cellectis-sa-amid-key-clinical-and-financial-milestones-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-for-cellectis-sa-amid-key-clinical-and-financial-milestones-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLLS"],"gpt_icon":0},{"id":"2582803070","title":"European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2582803070","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582803070?lang=en_us&edition=fundamental","pubTime":"2025-11-11 00:05","pubTimestamp":1762790700,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts opened the week higher late Monday morning, rising 0.77% to 1,603.65 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies Cellectis  and Genfit , which climbed 12.2% and 7.2% respectively. They were followed by 3D printer company Materialise  and lender Banco Bilbao Vizcaya Argentaria , which advanced 4.8% and 2.4% respectively.The decliners from continental Europe were led by petroleum refiner Equinor  and telecommunications operator Telefonica , which fell 2.2% and 1.4% respectively. They were followed by consumer goods giant Unilever  and telecommunications company Ericsson , which were down 1% and 0.8% respectively.From the UK and Ireland, the gainers were led by alcoholic beverage company Diageo  and biotech firm Autolus Therapeutics , which rose 4.9% and 2.2% respectively. They were followed by pharmaceutical company AstraZeneca  and biopharmaceutical comp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUTL","LU2456880835.USD","BK4117","LU1829250122.USD","BK4546","LU2236285917.USD","MTLS","AZN","TEF","CLLS","UL","BK4023","BK4568","BDRX","DEO","DGE.UK","EQNR","AKTX","LU0084288595.USD","BK4007","BK4592","DAVA","DAVA.AU","BK4515","BBVA","SLN","BK4588","LU0689626769.HKD","LU0320765992.SGD","AFG","BK4020","BK4183","GNFT","BK4554","LU0648005311.SGD","BK4559","BK4107","AMRN","BK4169","BK4207","BK4201","ULVR.UK","LU0124676726.USD","LU2462157665.USD","UN","BK4134","LU0889565916.HKD","ERIC","LU0109394709.USD","BK4591"],"gpt_icon":0},{"id":"2582695826","title":"Barclays Reaffirms Their Buy Rating on Cellectis SA (CLLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582695826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582695826?lang=en_us&edition=fundamental","pubTime":"2025-11-10 16:55","pubTimestamp":1762764954,"startTime":"0","endTime":"0","summary":"In a report released today, Gena Wang from Barclays maintained a Buy rating on Cellectis SA, with a price target of $8.00. According to TipRanks, W...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-cellectis-sa-clls-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-cellectis-sa-clls-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLLS"],"gpt_icon":0},{"id":"2581312578","title":"Cellectis Q3 Adj. EPS $0.02 Beats $(0.28) Estimate, Sales $37.164M Beat $6.900M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581312578","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581312578?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:32","pubTimestamp":1762551146,"startTime":"0","endTime":"0","summary":"Cellectis (NASDAQ:CLLS) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.28) by 107.19 percent. This is a 109.09 percent increase over losses of $(0.22) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48735396/cellectis-q3-adj-eps-0-02-beats-0-28-estimate-sales-37-164m-beat-6-900m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Cellectis Q3 Adj. EPS $0.02 Beats $(0.28) Estimate, Sales $37.164M Beat $6.900M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLLS"],"gpt_icon":0},{"id":"2581200968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2581200968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581200968?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Ares Cmm Rl Est                                 3Q      (.03)  6:00 AM. ·CNH Indus NV                                     3Q       .13   6:30 AM. ·Delek US Hldgs                                    3Q       .17   7:00 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSG","AKBA","AXL","AQN","DDI","BARK","AMCX","BEKE","ADCT","CGC","CLLS","B","ASRT","CAMT","AMBC","BTDR","CTEV","BW","CGEN","DHX","CEG","CNH","BLTE","DCBO","ATMU","AIRS","BXSL","ANIP","BODI","BAM","CHGG","ARCT","APEI","CLMT","ALXO","BDTX","ACRE","BCSF","BIP","ANTA","TASK","DCGO","BEN","BAK","CEVA","BALY","CAPR","BKV"],"gpt_icon":1},{"id":"2581779137","title":"Cellectis SA  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779137","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581779137?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:02","pubTimestamp":1762354932,"startTime":"0","endTime":"0","summary":"Cellectis SA  expected to post a loss of23cents a share - Earnings Preview Cellectis SA CLLS.OQ, CLLS.O is expected to  show a fall in quarterly revenue when it reports  results on November 7 for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL8N3WH28Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","BK4139"],"gpt_icon":0},{"id":"2580627248","title":"European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2580627248","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580627248?lang=en_us&edition=fundamental","pubTime":"2025-11-04 00:24","pubTimestamp":1762187093,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were little changed late Monday morning, edging 0.04% lower to 1,592.21 on the S&P Europe Select ADR Index.From continental Europe, t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0006061336.USD","BK4142","BK4554","BTI","ASND","LU0320765992.SGD","ERIC","BDRX","NOK","BK4075","GNFT","BK4559","BK4139","BTI.AU","DGE.UK","LU0889565916.HKD","BK4117","BK7505","BK4547","IHG","LU2543165471.USD","ING.AU","BK4591","OPRA","LU0109394709.USD","BK4585","BK4588","CLLS","BK4169","BK7141","WPP.AU","EDAP","SLN","BK4515","BK4009","DEO","BK4020","AFG","BK4023","BK4082","ING","IE00BMPRXN33.USD","BCYC","WPP","BK4207","BK4107","BK7062","PUK","BK4162","IE00BMPRXR70.SGD"],"gpt_icon":1},{"id":"2580143622","title":"Cellectis to present development update for eti-cel at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580143622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580143622?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:25","pubTimestamp":1762179916,"startTime":"0","endTime":"0","summary":"Cellectis (CLLS) announced the acceptance of two abstracts for poster presentation at the American Society of Hematology, ASH, 2025 annual meeting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cellectis-to-present-development-update-for-eti-cel-at-ash-2025-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cellectis-to-present-development-update-for-eti-cel-at-ash-2025-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4109","BK4139","ASH","CLLS","LU2463526074.USD"],"gpt_icon":0},{"id":"2580416193","title":"Cellectis to Report Third Quarter Financial Results on November 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416193","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416193?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:30","pubTimestamp":1761942600,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  31, 2025  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/31/3178649/0/en/Cellectis-to-Report-Third-Quarter-Financial-Results-on-November-7-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","BK4139"],"gpt_icon":0},{"id":"2580491482","title":"Cellectis SA  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580491482","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580491482?lang=en_us&edition=fundamental","pubTime":"2025-11-01 00:21","pubTimestamp":1761927701,"startTime":"0","endTime":"0","summary":"Cellectis SA  expected to post a loss of23cents a share - Earnings Preview Cellectis SA CLLS.OQ, CLLS.O is expected to  show a fall in quarterly revenue when it reports  results on November 3 (estimat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC1XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","BK4139"],"gpt_icon":0},{"id":"2577741988","title":"European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2577741988","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577741988?lang=en_us&edition=fundamental","pubTime":"2025-10-21 23:06","pubTimestamp":1761059203,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were down late Tuesday morning, declining 0.2% to 1,586.32 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by telecommunications company Ericsson  and pharmaceutical company Sanofi, which rose 1.3% and 0.6% respectively. They were followed by petroleum refiner Equinor  and accommodations booking site trivago , which were up 0.4% and 0.3% respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis  and biotech firm Evaxion , which fell 7% and 6% respectively. They were followed by semiconductor company Sequans Communications  and pharmaceutical company Ascendis Pharma , which were down 3.5% and 3.3% respectively.From the UK and Ireland, the gainers were led by software firm Endava  and cruise line operator Carnival , which advanced 4.3% and 2.4% respectively. They were followed by educational publisher Pearson  and lender HSBC , which increased 1.6% ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQNR","LU0149721374.USD","BK1231","BK4585","PSO","ERIC","LU0164880469.USD","BK4139","LU0634319403.HKD","BK4521","CUK","HSHD.SI","AFG","BK4107","LU0052756011.USD","LU0417516738.SGD","BK4020","HSBA.UK","LU0648005311.SGD","LU1481107354.HKD","LU0516422366.SGD","TRVG","SQNS","LU0084288595.USD","IE00BFXG1179.USD","ASND","DAVA.AU","LU2236285917.USD","DAVA","LU0348735423.USD","BK4117","BK1601","EVAX","NCNA","AUTL","BK4077","BK4204","BK4591","ADAPY","HSBC","03143","BK4082","00005","LU0889565916.HKD","LU0310800965.SGD","ADAP","BK4141","CLLS","LU0540923850.HKD","TRIB","SNY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cellectis.com","stockEarnings":[{"period":"1week","weight":0.1009},{"period":"1month","weight":0.4451},{"period":"3month","weight":0.7215},{"period":"6month","weight":2.8571},{"period":"1year","weight":1.6443},{"period":"ytd","weight":1.85}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.006645},{"month":2,"riseRate":0.4,"avgChangeRate":-0.079349},{"month":3,"riseRate":0.6,"avgChangeRate":-0.034139},{"month":4,"riseRate":0.363636,"avgChangeRate":0.028145},{"month":5,"riseRate":0.636364,"avgChangeRate":0.053843},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.075756},{"month":7,"riseRate":0.363636,"avgChangeRate":0.040955},{"month":8,"riseRate":0.727273,"avgChangeRate":0.056431},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.108663},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.048106},{"month":11,"riseRate":0.545455,"avgChangeRate":0.268959},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.003106}],"exchange":"NASDAQ","name":"Cellectis SA","nameEN":"Cellectis SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cellectis SA(CLLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cellectis SA(CLLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cellectis SA,CLLS,Cellectis SA股票,Cellectis SA股票老虎,Cellectis SA股票老虎国际,Cellectis SA行情,Cellectis SA股票行情,Cellectis SA股价,Cellectis SA股市,Cellectis SA股票价格,Cellectis SA股票交易,Cellectis SA股票购买,Cellectis SA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cellectis SA(CLLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cellectis SA(CLLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction